ATE407928T1 - Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung - Google Patents

Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung

Info

Publication number
ATE407928T1
ATE407928T1 AT02758416T AT02758416T ATE407928T1 AT E407928 T1 ATE407928 T1 AT E407928T1 AT 02758416 T AT02758416 T AT 02758416T AT 02758416 T AT02758416 T AT 02758416T AT E407928 T1 ATE407928 T1 AT E407928T1
Authority
AT
Austria
Prior art keywords
amino
production
pharmaceutical composition
kinase inhibitors
compounds
Prior art date
Application number
AT02758416T
Other languages
English (en)
Inventor
Maurizio Pulici
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE407928T1 publication Critical patent/ATE407928T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT02758416T 2001-08-07 2002-07-30 Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung ATE407928T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/922,729 US20030073692A1 (en) 2001-08-07 2001-08-07 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE407928T1 true ATE407928T1 (de) 2008-09-15

Family

ID=25447517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758416T ATE407928T1 (de) 2001-08-07 2002-07-30 Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung

Country Status (23)

Country Link
US (2) US20030073692A1 (de)
EP (1) EP1427708B1 (de)
JP (1) JP2005501085A (de)
KR (1) KR20040029400A (de)
CN (2) CN1538960A (de)
AT (1) ATE407928T1 (de)
BR (1) BR0211807A (de)
CA (1) CA2455759A1 (de)
CO (1) CO5560573A2 (de)
CZ (1) CZ2004305A3 (de)
DE (1) DE60228857D1 (de)
DK (1) DK1427708T3 (de)
EA (1) EA006645B1 (de)
ES (1) ES2315385T3 (de)
IL (1) IL159843A0 (de)
MX (1) MXPA04000905A (de)
NO (1) NO20040547L (de)
NZ (1) NZ531310A (de)
PL (1) PL368440A1 (de)
PT (1) PT1427708E (de)
SI (1) SI1427708T1 (de)
WO (1) WO2003014090A1 (de)
ZA (1) ZA200401316B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ547481A (en) * 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7648978B2 (en) * 2004-09-28 2010-01-19 Angion Biomedica Corp. Small molecule modulators of cytokine activity
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
TWI378925B (en) * 2005-01-14 2012-12-11 Gilead Connenticut Inc Certain substituted ureas as modulators of kinase activity
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
CA2645728A1 (en) * 2006-03-20 2007-09-27 Edward Boyd (Deceased) Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
JP2009541217A (ja) * 2006-06-15 2009-11-26 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤としての２−オキシベンズアミド誘導体
US20090281086A1 (en) * 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008061108A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
ES2546816T3 (es) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
ATE525370T1 (de) * 2007-10-11 2011-10-15 Glaxo Group Ltd Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
AU2008313467B2 (en) * 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
US8772326B2 (en) 2008-07-10 2014-07-08 Anigion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
BR122021018683B1 (pt) * 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
WO2010042649A2 (en) 2008-10-10 2010-04-15 Amgen Inc. PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
US20110098304A1 (en) * 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity
TW201114756A (en) * 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
ES2454567T3 (es) * 2010-04-16 2014-04-10 Abbvie Inc. Inhibidores de quinasas ftalazin-(2h)-ona
CN103058927B (zh) * 2011-10-21 2015-04-22 华国媛 一种喹啉衍生物及其应用
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
CN107298640B (zh) * 2017-07-19 2020-08-04 曲阜师范大学 一种亚甲基酮化合物的制备方法及其应用
CN114026085A (zh) 2019-04-11 2022-02-08 安吉昂生物医药公司 (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
US11492351B2 (en) * 2019-09-12 2022-11-08 Mirati Therapeutics, Inc. MTA-cooperative PRMT5 inhibitors
EP4458812A1 (de) * 2021-12-27 2024-11-06 Medshine Discovery Inc. Pyrazol-1(2h)-phthalazinonverbindung und anwendung davon
CN116903611A (zh) * 2022-01-26 2023-10-20 上海优理惠生医药有限公司 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用
CN116178347B (zh) * 2022-06-29 2025-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (de) * 1957-05-07
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
EP0634404A1 (de) * 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazinderivate und deren Verwendung als pestizides Mittel
JPH0961961A (ja) * 1995-08-21 1997-03-07 Fuji Photo Film Co Ltd 熱現像感光材料
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP0875512A3 (de) 1997-04-16 1999-04-07 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Naphthylpiperazin-Derivate mit antipsychotischer Wirkung
WO2000061556A1 (en) * 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same

Also Published As

Publication number Publication date
CZ2004305A3 (cs) 2004-08-18
US7432263B2 (en) 2008-10-07
PT1427708E (pt) 2008-11-20
ES2315385T3 (es) 2009-04-01
SI1427708T1 (sl) 2008-12-31
CA2455759A1 (en) 2003-02-20
WO2003014090A1 (en) 2003-02-20
US20030073692A1 (en) 2003-04-17
US20050020583A1 (en) 2005-01-27
PL368440A1 (en) 2005-03-21
EP1427708A1 (de) 2004-06-16
JP2005501085A (ja) 2005-01-13
EP1427708B1 (de) 2008-09-10
BR0211807A (pt) 2004-09-21
CN101085759A (zh) 2007-12-12
KR20040029400A (ko) 2004-04-06
CN1538960A (zh) 2004-10-20
EA200400283A1 (ru) 2004-08-26
IL159843A0 (en) 2004-06-20
EA006645B1 (ru) 2006-02-24
DK1427708T3 (da) 2008-11-24
DE60228857D1 (de) 2008-10-23
ZA200401316B (en) 2005-03-10
NZ531310A (en) 2006-02-24
MXPA04000905A (es) 2004-04-02
NO20040547L (no) 2004-03-03
CO5560573A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
DE60228857D1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
UY27592A1 (es) Nuevo uso
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427708

Country of ref document: EP

REN Ceased due to non-payment of the annual fee